Over 30 validated syngeneic models for immune profiles in spleen, tumor and blood, with rapid expanding model panel

Efficacy studies including immune check point inhibitors

Anti-PD-1 response was well validated in these models

• Highly response Model : MC38, Renca

• Medium response : CT26, EMT6, MB49

• Low response : LL2, TC1, B16F10, 4T1

Treatment associated TIL (Tumor Infiltrate Lymphocyte) profiling by FACS analysis